Core B is a Neuropathology and Biomarker Core (NP Core) that plays a vital role in the UCSF FTD PPG. FTLD neuropathology has become increasingly exciting and complex in recent years, with major advances arising from work accomplished through this PPG. In this renewal application, we propose to continue to cultivate a world-class FTLD-oriented neurodegenerative disease brain bank at UCSF. The NP Core aims to: (1) Obtain CNS tissue for NP characterization and banking by performing timely autopsies on patients and healthy controls ascertained through the Clinical Core; (2) Analyze specimens and document NP diagnoses by dissecting a standard set of 23 tissue blocks for routine histological staining and systematic immunohistochemical characterization, resulting in semi-quantitative and quantitative assessments; (3) Enter NP findings into a comprehensive research-oriented database; (4) Bank CNS tissues, blood, plasma, and CSF, analyze CSF for putative diagnostic biomarkers, and distribute biospecimens to qualified investigators; (5) Engage with PPG collaborators in conducting FTLD clinico-pathological research by meeting regularly with PPG Project leaders who rely on NP Core data; and (6) Train the next generation of neuropathology leaders and clinical scientists grounded in neuropathology principles and methods by holding consensus and clinico- pathological conferencesThese core functions will support the aims of Projects 3 (Emotions), 4 (Clinical criteria), and 7 (Language) by providing final neuropathological diagnoses that serve as primary outcomes or grouping variables as well as semi-quantitative and/or quantitative regional pathological data. Moreover, the NP Core will help to further develop a unique bank of specially handled CNS tissues (brain, spinal cord, and CSF) for ongoing and future FTLD molecular, translational, clinicopathological, and biomarker discovery research.
| Erkkinen, Michael G; Zúñiga, Raquel Gutiérrez; Pardo, Cristóbal Carnero et al. (2018) Artistic Renaissance in Frontotemporal Dementia. JAMA 319:1304-1306 |
| Schneider, Raphael; McKeever, Paul; Kim, TaeHyung et al. (2018) Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. J Neurol Neurosurg Psychiatry 89:851-858 |
| Ljubenkov, Peter A; Staffaroni, Adam M; Rojas, Julio C et al. (2018) Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann Clin Transl Neurol 5:1250-1263 |
| La Joie, Renaud; Bejanin, Alexandre; Fagan, Anne M et al. (2018) Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90:e282-e290 |
| Kim, Eun-Joo; Brown, Jesse A; Deng, Jersey et al. (2018) Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series. J Neurol 265:2960-2971 |
| Henry, Maya L; Hubbard, H Isabel; Grasso, Stephanie M et al. (2018) Retraining speech production and fluency in non-fluent/agrammatic primary progressive aphasia. Brain 141:1799-1814 |
| Nana, Alissa L; Sidhu, Manu; Gaus, Stephanie E et al. (2018) Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathol : |
| Vatsavayai, Sarat C; Nana, Alissa L; Yokoyama, Jennifer S et al. (2018) C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies. Acta Neuropathol : |
| Ossenkoppele, Rik; Rabinovici, Gil D; Smith, Ruben et al. (2018) Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 320:1151-1162 |
| Mandelli, Maria Luisa; Welch, Ariane E; Vilaplana, Eduard et al. (2018) Altered topology of the functional speech production network in non-fluent/agrammatic variant of PPA. Cortex 108:252-264 |
Showing the most recent 10 out of 607 publications
